Ploeger B., Cleton A., Keunecke A., Bruix J., Meinhardt G. Population pharmacokinetics (popPK) to evaluate the effect of intrinsic and extrinsic factors on regorafenib (REG) exposure in REG studies including patients with hepatocellular carcinoma (HCC). The American Society of Clinical Oncology – Gastrointestinal Cancers Symposium, 2017.
Solms A., Reinecke I., Fiala-Buskies S., Keunecke A., Drenth H.J., Bruix, J., Meinhardt G., Cleton A., Ploeger, B. Exposure-response relationship of regorafenib efficacy in patients with hepatocellular carcinoma. European Journal of Pharmaceutical Sciences: S149-S153, 2017. [Link to publication]
Snelder N., Drenth H., Bergmann K., Wood N., Hibberd M. and Scott G., PKPD modelling of the relationship between testosterone and PSA in patients with prostate cancer during treatment with leuprorelin. What is the optimal testosterone level?, PAGE.(2015) [Link to publication]
Jongh J.d. and Ploeger B., A population PD model for effects of the cytostatic drugs Irinotecan and Temozolomide on Rh18 rabdomyosarcoma xenografts in mice. Noordwijkerhout.(2010).
Erp N.P.v., Baker S.D., Zandvliet A.S., Ploeger B.A., Hollander M.d., Chen Z., Hartigh J.d., Konig-Quartel J.M., Guchelaar H.J. and Gelderblom H., Marginal increase of sunitinib exposure by grapefruit juice, Cancer Chemother Pharmacol, 29: 29, 2010.
- « Previous
- 1
- 2